Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protist enteroparasites in wild boar (Sus scrofa ferus) and black Iberian pig (Sus scrofa domesticus) in southern Spain: a protective effect on hepatitis E acquisition?
Rivero-Juarez A, Dashti A, López-López P, Muadica AS, Risalde MLA, Köster PC, Machuca I, Bailo B, de Mingo MH, Dacal E, García-Bocanegra I, Saugar JM, Calero-Bernal R, González-Barrio D, Rivero A, Briz V, Carmena D. Rivero-Juarez A, et al. Parasit Vectors. 2020 Jun 3;13(1):281. doi: 10.1186/s13071-020-04152-9. Parasit Vectors. 2020. PMID: 32493465 Free PMC article.
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Rivero-Juárez A, Mira JA, Pérez-Camacho I, Macías J, Camacho A, Neukam K, Torre-Cisneros J, Merchante N, Pineda JA, Rivero A; Viral Hepatitis Study Group, part of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) (Andalusian Society for Infectious Diseases). Rivero-Juárez A, et al. J Antimicrob Chemother. 2011 Jun;66(6):1351-3. doi: 10.1093/jac/dkr091. Epub 2011 Mar 17. J Antimicrob Chemother. 2011. PMID: 21415037
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A. Rivero-Juárez A, et al. J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11. J Antimicrob Chemother. 2012. PMID: 21990051
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
Rivero-Juárez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, Marquez-Solero M, Caruz A, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A. Rivero-Juárez A, et al. PLoS One. 2012;7(11):e48959. doi: 10.1371/journal.pone.0048959. Epub 2012 Nov 8. PLoS One. 2012. PMID: 23145040 Free PMC article. Clinical Trial.
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
Neukam K, Almeida C, Caruz A, Rivero-Juárez A, Rallón NI, Di Lello FA, Herrero R, Camacho A, Benito JM, Macías J, Rivero A, Soriano V, Pineda JA. Neukam K, et al. J Antimicrob Chemother. 2013 Apr;68(4):915-21. doi: 10.1093/jac/dks488. Epub 2012 Dec 12. J Antimicrob Chemother. 2013. PMID: 23243129
203 results